REYKJAVIK,Iceland,Feb. 17,2025 -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology,highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine,an L-type calcium channel blocker (LTCC),as a foundation for a novel therapy for ADHD. The findings provide robust validation of 3Z's cutting-edge high-throughput drug discovery platform and introduce new avenues for non-stimulant-based ADHD treatment.

ADHD is a prevalent neurodevelopmental disorder with limited treatment options. Current stimulant medications,such as methylphenidate,offer benefits to some but are often associated with side effects,abuse potential,and a high non-response rate. 3Z Pharmaceuticals is committed to addressing these gaps by pioneering alternative,non-stimulant therapeutics.

In this newly published study,researchers at 3Z,integrated cross-species behavioral assays,Mendelian Randomization analysis,and human genetic data to demonstrate amlodipine's therapeutic potential. Key findings include:

Behavioral Rescue in ADHD Models: Amlodipine significantly reduced hyperactivity in Spontaneously Hypertensive Rats and improved impulsivity in the adgrl3.1-/- zebrafish model of ADHD,providing cross-species validation of its efficacy.

Blood-Brain Barrier Penetration & Neural Impact: Surprisingly traditional penetration studies confirmed that amlodipine crosses the blood-brain barrier,where it modulates neuronal activation,countering the assumption of poor brain penetration.

Genetic Evidence via Mendelian Randomization: Human genetic analysis linked ADHD risk to variations in LTCC genes (CACNA1C,CACNB1,CACNA2D3),which are direct targets of amlodipine,reinforcing its mechanistic potential in ADHD therapy.

Clinical Relevance in Human Populations: Polygenic risk score analysis using the UK Biobank demonstrated that individuals with a high ADHD genetic burden who were prescribed amlodipine exhibited reduced ADHD-related symptoms,independent of its antihypertensive effects.

Dr. Karl Karlsson a neuroscientist,CEO of 3Z Pharmaceuticals and Professor of Biomedical Engineering at Reykjavik University,commented on the study's impact:

"This research represents a paradigm shift in ADHD therapeutics. Our findings not only validate the mechanism impacted by amlodipine as a promising candidate for non-stimulant ADHD treatment but also underscore the power of our high-throughput screening and genetic modeling approaches,performed in close alliance with biotx.ai. This is an exciting step forward in our mission to deliver more effective and well-tolerated treatments for ADHD."

Building on these findings,3Z Pharmaceuticals is advancing a variant of the therapeutic towards clinical development,leveraging its established safety profile and precise mechanism of action to introduce transformative ADHD therapy.

Media Contact:

Name: Karl Ægir Karlson

Title: CEO

3Z Pharmaceuticals

Email: Karlsson@3z.is

Phone: +354-8256467

Link to paper:https://www.nature.com/articles/s41386-025-02062-x

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/3z-ehf/r/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh,c4106638